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The BIRC5 (Survivin) gene is located at chromosome 17q in the region that is frequently
gained in high risk neuroblastoma. BIRC5 is strongly over expressed in neuroblastoma
tumour samples, which correlates to a poor prognosis. We recently validated BIRC5 as a
potential therapeutic target by showing that targeted knock down with shRNA’s triggers
an apoptotic response through mitotic catastrophe. We now tested YM155, a novel small
molecule selective BIRC5 suppressant that is currently in phase I/II clinical trials. Drug
response curves showed IC50 values in the low nM range (median: 35 nM, range:
0.5–>10,000 nM) in a panel of 23 neuroblastoma cell lines and four TIC-lines, which resulted
from an apoptotic response. Nine out of 23 cell lines were relatively resistant to YM155 with
IC50 values >200 nM, although in the same cells shRNA mediated knock down of BIRC5
caused massive apoptosis. Analysis of differentially expressed genes between five most
sensitive and five most resistant cell lines using Affymetrix mRNA expression data revealed
ABCB1 (MDR1) as the most predictive gene for resistance to YM155. Inhibition of the multi-
drug resistance pump ABCB1 with cyclosporine or knockdown with shRNA prior to treat-
ment with YM155 demonstrated that cell lines with ABCB1 expression became 27–695
times more sensitive to YM155 treatment.
We conclude that most neuroblastoma cell lines are sensitive to YM155 in the low nM
range and that resistant cells can be sensitised by ABCB1 inhibitors. Therefore YM155 is
a promising novel compound for treatment of neuroblastoma with low ABCB1 expression.
 2011 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction somal passenger complex during mitosis. Inactivation ofBIRC5 (Survivin) is an inhibitor of apoptosis protein (IAP) with
a crucial function in cell cycle and apoptotic signalling. In the
intrinsic apoptotic pathway it can bind and inhibit the pro-
apoptotic protein DIABLO and it can bind and stabilise XIAP,
another IAP. Inhibition of this function of BIRC5 induces
apoptosis by activating the intrinsic apoptotic pathway.1–3 In
addition, BIRC5 can stabilise microtubules in the chromo-nt of Oncogenomics, M
therlands. Tel.: +31 2056
(J.J. Molenaar).
he Elsevier OA license. BIRC5 can therefore also lead to mitotic catastrophe which
activates the intrinsic apoptotic pathway via p53 and Caspase
2.3–7 Genomic aberrations of the BIRC5 locus at 17q occur in
several malignancies. BIRC5 is gained in almost all high risk
neuroblastoma which is a paediatric tumour that originates
from the neural crest derived precursor cells of the sympa-
thetic nervous system.8–10 BIRC5 over expression in these
tumours strongly correlates to a poor prognosis. BIRC51-132, Academic Medical Center – University of Amsterdam,
67536; fax: +31 206918626.
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catastrophe, suggesting that in these tumour cells the crucial
function of BIRC5 is microtubule stabilisation.11
In addition to gain of the BIRC5 locus at 17q, only few other
aberrations in apoptotic signalling have been reported in neu-
roblastoma tumours and cell lines.12,13 P53 mutations are rare
and many cell line experiments showed that p53 can be acti-
vated to induce apoptosis.14,15 Caspase 8 is hypermethylated
and thereby inactive in some neuroblastoma resulting in an
inactive extrinsic apoptotic pathway.16 And finally BCL2 is of-
ten over expressed in neuroblastoma tumours and has been
found to be a target for therapy.17,18
Thus, BIRC5 is one of the few drugged targets in the intrin-
sic apoptotic pathway. This warrants further validation in
neuroblastoma since current treatment regimens can only
cure 25–35% of high stage neuroblastoma patients and there
is a strong need for new targeted therapies.8–10 BIRC5 has
shown to be a viable therapeutic target and several new strat-
egies for inhibiting BIRC5 have recently become available. The
locked nucleic acid (LNA)19 based antisense molecule
EZN3042 was effective in vitro in NB cells.11 The anti-BIRC5
antisense LNA oligonucleotide LY2181308 (gataparsen so-
dium) is currently being tested in phase II clinical trials in
solid tumours and BIRC5 based vaccines are currently in
phase I/II clinical trial.20 Though targeted therapy by anti-
sense based compounds can be effective in haematological
malignancies, they have been disappointing in solid tumours.
A promising new small molecule BIRC5 suppressant is YM155,
developed by Astellas Pharma. This compound was selected
by high throughput screening with a BIRC5 Promoter Lucifer-
ase Assay and inhibits mRNA expression of BIRC5.21 Phase I/II
clinical ‘single agent’ trials showed acceptable toxicity in pa-
tients with advanced solid malignancies.22,23 In a phase II trial
in melanoma the pre-specified criterion for success was not
reached,24 but in non-small-cell-lung-cancer 5% of the pa-
tients showed a partial response, and 38% showed stable dis-
ease.25 YM155 has also induced responses in a phase I trial in
patients with non-Hodgkin’s lymphoma or prostate cancer.23
In this paper we investigated the efficacy of YM155 in 23
neuroblastoma cell lines and four neuroblastoma ‘tumour
initiating cell’ (TIC) lines. First, we validated BIRC5 as a ther-
apeutic target by lentiviral shRNA mediated silencing of
BIRC5, which resulted in massive apoptosis in all six neuro-
blastoma cell lines tested. Subsequent assays using YM155
induced apoptosis in the majority of 23 tested neuroblas-
toma cell lines as well. Surprisingly, some cell lines that
were sensitive for targeted silencing using BIRC5 shRNA
were resistant to YM155. Analysis of mRNA profiles of sensi-
tive and insensitive cell lines identified the multi-drug resis-
tance pump ABCB1 (MDR1),26–28 as the best predictor of
resistance. Inhibition of ABCB1 with cyclosporine or lentivi-
ral shRNA sensitised the resistant cell lines to YM155 in-
duced apoptosis.
2. Methods
2.1. Cell lines
All cell lines were grown in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% foetal calf serum,10 mM L-glutamine, 10 U/ml penicillin/streptomycin, non-
essential amino acids (1·) and 10 lg/ml streptomycin. Cells
were maintained at 37 C under 5% CO2. For primary refer-
ences of these cell lines, see Molenaar et al.29 The tumour ini-
tiating cell (TIC) lines were isolated directly from patient
tumour or bone marrow cells and cultured in neural specific
stem cell medium (400 ml DMEM glutamax, 133 ml F12
medium, 2% B27, 20 ng/ml EGF, 40 ng/ml FGF, 10 U/ml penicil-
lin/streptomycin) as described previously.30
2.2. Lentiviral shRNA production and transduction
Lentiviral particles were produced in HEK293T cells by
cotransfection of lentiviral vector containing the short hair-
pin RNA (shRNA) with lentiviral packaging plasmids pMD2G,
pRRE and pRSV/REV using FuGene HD. Supernatant of the
HEK293T cells was harvested at 48 and 72 h after transfection,
which was purified by filtration and ultracentrifuging. The
concentration was determined by a p24 ELISA.
Cells were plated in a 10% confluence. After 24 h cells were
transduced with lentiviral BIRC5 shRNA (Sigma,
TRCN0000073720; coordinates: chromosome 17; 76212781–
76212801; hg19), or ABCB1 shRNA B5 and B7 (Sigma,
TRCN0000059684; coordinates: chromosome 7; 87190611–
87190631; hg19, and TRCN0000059686; coordinates: chromo-
some 7; 87175290–87175310; hg19) in various concentrations
(multiplicity of infection (MOI): 1–3). SHC-002 shRNA (non-tar-
geting shRNA: CAACAAGATGAAGAGCACCAA) was used as a
negative control. Twenty-four hours after transduction
medium was refreshed and puromycin was added to deter-
mine the efficacy of transduction. Protein was harvested 72 h
after transduction and analysed by Western blot. Nuclei were
harvested 48 and 72 h after transfection for FACS analysis.2.3. Lentiviral over expression clones
BIRC5 over expression constructs 7 and 10 were produced
from a PCR product of BIRC5 (CCDS11755.1: isoform 1) that
was obtained from IMR32 cDNA (primers: TATATAGGATCC-
ATTAACCGCCAGATTTGA/TATATAGAATTCGGTGGCACCAGGGA-
ATAAAC) and cloned into pLenti4/TO/V5-Dest according to
the manufacturer’s procedures (Invitrogen). The sequence
has been checked using the manufacturer’s primers (pL4-
TO/V5 fwd and pL4-dest rev).2.4. Compounds
YM155 (provided by Astellas Pharma) was dissolved in
DMSO in a stock concentration of 10 mM. It was added to
the cells in concentrations from 0.1 nM to 10 lM 24 h after
plating the cells in 10–30% confluence. Cyclosporine (Sigma,
C3662) was added to the cells in a concentration of 5 lM,
24 h after plating. The cells were incubated with cyclospor-
ine for 1 h before YM155 was added without removal of
cyclosporine.
RNA extraction and Affymetrix profiling, MTT-assay,
Western blotting and antibodies, FACS analysis and Crys-
tal Violet assays are described in the Supplementary
data.
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3.1. BIRC5 shRNA induces apoptosis in neuroblastoma cell
lines
We first validated BIRC5 as a drug target by silencing the
expression using shRNA targeting the coding sequence ofFig. 1 – BIRC5 shRNA induces apoptosis in neuroblastoma cell l
shRNA or SHC002 pictures were made with a 100· magnitude. (b
were incubated with BIRC5, PARP, and Actin antibodies.BIRC5 in a series of neuroblastoma cell lines. This resulted
in a massive phenotypic response 72 h after transduction in
all six tested neuroblastoma cell lines (Fig. 1a). Western blot
analysis confirmed targeted knockdown of BIRC5 in all cell
lines tested. BIRC5 silencing resulted in PARP cleavage which
confirms that the cells die from an apoptotic response
(Fig. 1b). These findings establish targeted silencing of BIRC5ines. (a) Seventy-two hours after transduction with BIRC5
) Protein lysates were made of the cells of (a). Western blots
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mour cells and we therefore decided to test the efficacy of
the small molecule BIRC5 suppressant YM155 in neuroblas-
toma cell lines.
3.2. YM155 sensitivity in neuroblastoma cell lines
First we determined the IC50 (concentration drug needed for
50% cell survival) for a panel of 23 neuroblastoma cell lines
using an MTT-assay. This showed that 14 out of 23 cell lines
were sensitive to YM155, with an IC50 below 200 nM (Table 1).
Examples of sensitive cell lines are SKNAS, IMR32 and
SMSKCNR of which the dose–effect curves show sensitivity
to YM155 in the low nM range (Fig. 2a). Pictures of SKNAS
and IMR32 illustrate the increasing phenotypic response after
treatment with accruing concentrations of YM155 (Suppl.
Fig. 1a) and Crystal Violet assays showed a clear decrease of
attached cells in SMSKCNR and SKNAS (Suppl. Fig. 1b). In
addition to classical cell lines, we tested the sensitivity of four
newly isolated TIC-lines to YM155. These cells were isolated
directly from patient tumour or bone marrow material and
maintained in neural stem cell specific medium. These TICTable 1 – Most neuroblastoma cell lines are sensitive to
YM155. The IC50 values were calculated from the curves as
presented in Fig. 2a. The IC50 values for YM155 of all 23
neuroblastoma cell lines and four TIC lines are shown in the
second column of this table.
Cell lines IC50 (nM)
IMR32 0.5
AMC691Ta 1.5
SKNAS 2
CHP134 3
AMC700Ba 3
SMSKCNR 4
AMC700Ta 5
GIMEN 6
LAN5 6
AMC 691Ba 7
LAN1 10
SHEP21N 12
AMC106 14
NMB 23
N206 35
SHEP2 39
SJNB8 73
SJNB12 78
SJNB6 192
SJNB10 306
SKNBE 356
NGP 375
SJNB1 496
UHGNP 1027
SHSY5Y 1282
SKNSH 6188
SKNFI 10,000
TR14 10,000
a TIC-lines.lines also showed sensitivity to YM155 in the low nM range
(Table 1).
3.3. YM155 causes apoptosis by specific silencing of BIRC5
To evaluate the phenotype after treatment with YM155, we
performed Western blot analysis. SKNAS and IMR32 showed
dose-dependent BIRC5 silencing, PARP cleavage occurred at
50 nM for SKNAS and 10 nM for IMR32 (Fig. 2b). FACS analysis
of SKNAS, IMR32 and SMSKCNR showed a large increase of
the sub-G1 fraction of 32-, 20- and 10-fold respectively, 48 h
after treatment with 10 nM YM155 (Fig. 2c). These findings
indicate that YM155 causes targeted silencing of BIRC5, which
induces apoptosis.
To verify if the apoptotic effect of YM155 is caused specif-
ically by BIRC5 inhibition, we induced ectopic BIRC5 over
expression in IMR32 clones with a BIRC5 cDNA construct un-
der control of a constitutively active CMV promoter. In two
independent IMR32-BIRC5 clones this resulted in rescue of
the YM155-induced loss of cell viability (Fig. 2d). If these cells
were also rescued from apoptosis induction we verified BIRC5
expression and PARP cleavage by Western blot and found a
clear partial rescue from apoptosis (Suppl. Fig. 1c). This con-
firms that the apoptotic response after YM155 exposure re-
sults from targeted inhibition of BIRC5.
3.4. ABCB1 is the most predictive gene for YM155
resistance
These findings establish YM155 as an effective targeted com-
pound in a series of neuroblastoma cell lines. However, in the
full panel of 23 neuroblastoma cell lines the IC50 varied from
0.5 nM up to 10,000 nM and nine out of 23 cell lines were rel-
atively resistant to YM155 with an IC50 >200 nM (Table 1). We
used the R2 bioinformatic platform, which contains Affyme-
trix mRNA expression data of 23 neuroblastoma cell lines,
to identify genes that might predict or even cause resistance
to YM155. Differential expression analysis between the five
most sensitive versus the five most resistant classical cell
lines, based on IC50 values, showed that ABCB1 (MDR1) was
the most differentially expressed gene in the analysis
(p < 0.02 Student T-test after FDR correction). ABCB1 is an out-
lier as revealed from the volcano-plot of all genes, indicating
its significance (Fig. 3a). Cell lines with a high ABCB1 expres-
sion were resistant to YM155, whereas cell lines with a low
ABCB1 expression were sensitive (Fig. 3b).
3.5. Targeted ABCB1 silencing can restore YM155
sensitivity in resistant cell lines
To confirm the functional importance of ABCB1, we combined
targeted inhibition of the multi-drug resistance pump with
YM155 treatment. Cyclosporine can effectively and specifi-
cally inhibit ABCB1.27,31 Eight YM155 resistant cell lines and
one sensitive cell line as a control were treated with 5 lM of
cyclosporine 1 h prior to treatment with YM155. This resulted
in a strong increase of sensitivity to YM155 of all cell lines
with a high ABCB1 expression (Suppl. Fig. 2a). Crystal Violet
assays revealed that cyclosporine pretreated SKNSH cells sur-
vived much less efficiently than YM155 only treated cells
Fig. 2 – YM155 induces apoptosis in most neuroblastoma cell lines. (a) IC50 curves of SKNAS, IMR32 and SMSKCNR 48 h after
YM155 treatment are shown. The Y-axis represents the percentage of cell survival; the X-axis represents the concentration
YM155 in nM. (b) Western blots of SKNAS and IMR32 were incubated with BIRC5, PARP and actin antibodies. The
concentrations YM155 used are shown above the blots in nM. (c) FACS analysis of SKNAS, IMR32 and SMSKCNR 72 h after
treatment with YM155. The percentage of the sub G1 (apoptotic) fraction is presented in the graph. (d) MTT assay of IMR32
cells that were stably transduced with BIRC5 over expression construct (IMR32-Surv-7 and IMR32-Surv-10) and treated with
YM155 for 24 h. The Y-axis represents the percentage of cell survival; the X-axis represents the concentration YM155.
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duced the IC50 values of all cell lines with ABCB1 expression
by 27- up to 695-fold (Fig. 4a and Table 2). In SJNB12, which
has a very low expression of ABCB1, co-incubation with cyclo-
sporine did not result in a change of YM155 sensitivity
(Table 2). Western blot analysis of SKNSH, UHGNP and SHY5Ydemonstrated that BIRC5 was inhibited when cells were pre-
treated with cyclosporine, but not when cells were treated
with YM155 alone. In addition, cyclosporine pretreated cells
showed sensitisation to YM155 by an induction of PARP cleav-
age (Fig. 4b). Apoptosis was confirmed by FACS analysis,
which showed that the apoptotic sub G1 fraction strongly
Fig. 3 – ABCB1 is the most differentially expressed gene between YM155 sensitive and resistant cell lines. (a) Volcano-plot of
all genes based on Affymetrix Micro-array RNA expression data. The Y-axis represents the log10 of the P-value. The X-axis
represents the log-fold of the five most resistant cell lines (TR14, SKNFI, SKNSH, SHSY5Y, UHGNP) divided by the log-fold of
the five most sensitive cell lines (IMR32, SKNAS, CHP134, SMSKCNR, GIMEN). The arrow indicates ABCB1, which is the only
significantly differentially expressed outlier. (b) Relative ABCB1 RNA expression based on MAS5.0 corrected Affymetrix Micro-
array data (Y-axis) of the five most sensitive versus the five most resistant cell lines (X-axis). The horizontal line represents
the average expression.
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treated with cyclosporine before addition of YM155 (Fig. 4c).
We also knocked down ABCB1 in SKNSH with two lentivi-
ral shRNAs targeting different parts of the coding sequence of
ABCB1, which confirmed our findings with cyclosporine pre-
treated cells. The IC50 of SKNSH decreased from 370 nM in
the untransduced control and 347 nM in the cells transduced
with SHC002 to 35 and 29 nM in the cells transduced with
either of the ABCB1 shRNAs (Fig. 4d). Knockdown of both
ABCB1 shRNAs was validated as shown in Fig. 4e.
3.6. Clinical predictions with YM155 related biomarkers
ABCB1 is a multi-drug resistance pump which is involved in
chemoresistance in many types of cancer. Our results indi-
cate that ABCB1 is a potential biomarker for efficacy. The
ABCB1 mRNA expression pattern in neuroblastoma cell lines
suggests dichotomy. This is to a lesser extent reflected in
the neuroblastoma tumour series as shown in Suppl. Fig. 3a.
We chose a cut-off value of 200 nM (as indicated in the figure)
because at this value the slope of the samples ordered by
ABCB1 expression was the highest. Most interestingly, the
subset of tumours with low ABCB1 expression levels tends
to correlate with prognostic factors such as age, stage, sur-
vival and MYCN amplification (Suppl. Fig. 3a). Also, childrenwith a tumour with low ABCB1 expression have a poor prog-
nosis according to the Kaplan–Meier curve (p < 0.02 after Bon-
ferroni correction) (Suppl. Fig. 3b). This suggests that patients
with a poor prognosis are likely to be sensitive to YM155. In
addition, we investigated if BIRC5 could be a predictor for sen-
sitivity. However, we did not find a correlation between the
IC50 to YM155 and BIRC5 expression in our cell line panel
(Suppl. Fig. 3c) and BIRC5 can therefore not be used as a pre-
dictor for sensitivity in neuroblastoma patients. This also
holds true if we exclude the cell lines with high ABCB1
expression (data not shown).
4. Discussion
We conclude that 14 out of 23 neuroblastoma cell lines are
sensitive to YM155 in the low nM range. Most small molecule
compounds used in anticancer treatment are known to inhi-
bit a variety of genes. The lack of specificity is an important
cause of the severe side-effects of these compounds and it
is well established that blocking a single target with high po-
tency minimises the side-effects.32 YM155 was picked up by a
screen that was designed to select compounds in a chemical
compound library efficiently inhibiting the BIRC5 promoter.21
This resulted in a highly effective BIRC5 suppressant as was
validated in our experiments. We were able to rescue YM155
Fig. 4 – Resistant cell lines can be sensitised by cyclosporine or ABCB1 shRNA. (a) MTT-assay was performed 72 h after
treatment with YM155. Three cell lines that were treated with YM155 with or without cyclosporine are shown. The Y-axis
represents the percentage cell survival; the X-axis represents the concentration YM155 in nM. The dotted line is the curve for
YM155 without cyclosporine; the continuous line is the curve for the combination of YM155 and cyclosporine. (b) Western
blots were incubated with BIRC5, PARP and actin antibodies. Three cell lines are shown, the concentration YM155 is depicted
in nM. (c) FACS analysis of SKNSH and SHSY5Y treated with YM155 with or without cyclosporin. The percentage of the sub G1
(apoptotic) fraction is presented in the graph. (d) SKNSH cells were transduced with two different ABCB1 shRNAs (B5 and B7)
or with SHC002 (control virus). Seventy-two hours after transduction cells were treated with a concentration series of YM155.
Seventy-two hours after treatment an MTT-assay was performed as described previously. The Y-axis represents the
percentage of cell survival; the X-axis represents the concentration YM155 in lM. (e) Knockdown of ABCB1 protein in SKNSH
72 h after transduction with both ABCB1 shRNAs was checked by Western blot. Blots were incubated with ABCB1 and Actin
antibodies.
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Table 2 – Resistant cell lines can be sensitised by cyclosporine. The table represents the IC50 values for YM155 of all cell lines
of the panel with ABCB1 expression without and with pretreatment with cyclosporine (2nd and 3rd column), the ratio
between these two values (4th column) and the ABCB1 RNA expression (5th column).
cell lines IC50 (nM) IC50 + cyclo (nM) ratio ABCB1 expression
SJNB10 306 9 36 155
SKNBE 356 7 51 604
SJNB1 496 2 248 747
UHGNP 1027 7 147 655
SHSY5Y 1282 8 169 522
SKNSH 6188 9 695 568
SKNFI >10,000 366 27 581
TR14 >10,000 40 249 1100
SJNB12 78 66 1 12
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that YM155 is a highly specific BIRC5 suppressant. These find-
ings establish YM155 as an interesting compound for treat-
ment of neuroblastoma patients.
Most interestingly, also the four TIC lines we tested were
shown to be very sensitive to YM155. These TIC lines are cul-
tured in neural stem cell medium, grow in spheroids and have
been cultured only for a limited number of passages. There-
fore these cells are thought to be a better representation of
in vivo neuroblastoma tumours.33 In addition these cells have
been shown to have increased tumourigenicity in in vivo
models.
Analysis of the differential expression between the five
most sensitive and the five most resistant classical cell lines
revealed that increased expression of ABCB1 is a good predic-
tor for insensitivity to YM155. The other ABC transporters
that are known as a multi-drug resistant pump (ABCC1 and
ABCG2) did not reveal any significant correlation between
these two groups (data not shown). Inhibition of ABCB1 with
cyclosporine resulted in sensitisation of all resistant cell lines
with ABCB1 expression, which was confirmed by shRNA med-
iated silencing of ABCB1. Cyclosporine is originally used as an
immunosuppressant drug in patients after organ transplanta-
tion. It is also an active inhibitor of ABCB1; however for this
use high concentrations were needed and found to be toxic
in combination treatment presumably because cyclosporine
induced sensitisation of the bone marrow to chemo ther-
apy.27,34 Currently, new inhibitors of ABC transporters are in
clinical development, such as PSC833, V-104, tarquidar and
ONT-093.26–28 After clinical implementation these compounds
could be combined with YM155.
Still, targeted ABCB1 inhibition is currently not possible in
a clinical setting. The over expression of ABCB1 in neuroblas-
toma however can be used as a selection biomarker. BIRC5 is
over expressed in almost all high risk neuroblastoma and in
principle serves as drug target in these patients. As high
ABCB1 expression prevents effective targeting, we propose
to select ABCB1 negative patients for clinical testing of
YM155. Most interestingly, this group of patients tends to
have a very poor prognosis and new therapeutic options are
urgently needed in this specific subgroup.
Before YM155 can be used in a phase I/II clinical trial in
neuroblastoma patients, the compound needs to be validated
in a neuroblastoma mouse model. New compounds will onlybe used in neuroblastoma patients in combination with the
currently used cytostatics. Therefore these interactions need
to be evaluated. The knowledge that mitotic catastrophe is in-
volved in the apoptotic response after BIRC5 knockdown can
also guide compound combination strategies.11 Simultaneous
inhibition of other genes in the same signal transduction
pathway could lead to additional or synergistic effects. For
example AURKB inhibitors could potentially enhance the ef-
fect of BIRC5 inhibition as they both are part of the chromo-
somal passenger complex. Mitotic catastrophe results in an
apoptotic response via mitochondrial release of pro-apoptotic
proteins. Sensitisation of this downstream signal transduc-
tion pathway by BCL2 inhibitors or SMAC mimetics might
lead to synergism with a BIRC5 inhibitor. Based on in vivo
experiments and on knowledge about the efficacy of YM155
combined with other drugs, a phase I/II clinical trial can be
designed.
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